Mechanisms of Action and Critical Appraisal of Preclinical and Clinical Evidence for Green Banana (Musa spp.) and Banana-Derived Preparations in Obesity, Metabolic Syndrome and Type 2 Diabetes: A Narrative Review
Foods · 13.11.2026 · 15 (22) · 4067
DOI: 10.3390/foods15224067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Foods, online erschienen am 13.11.2026. Verfasst von Audrey Warnery und 6 weiteren Autor:innen. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Obesity, metabolic syndrome (MetS) and type 2 diabetes (T2D) share chronic low-grade inflammation, insulin resistance and gut dysbiosis. Green banana pulp provides type-2 resistant starch (RS2), whereas other constituents—including phenolics—occur in tissue- and cultivar-dependent profiles. This narrative review critically appraises banana-derived preparations in relation to adiposity, glycaemic control, inflammation and the gut–liver axis. Preparation-level effects are distinguished from findings on isolated compounds and from mechanisms established with other sources of resistant starch or polyphenols.
Methods
The core literature search covered PubMed, Scopus, Web of Science and ScienceDirect for 2000–2025. Historical and contextual sources were considered separately, and reporting was guided by SANRA.
Results
Banana starch and fibre interventions modify the microbiota and increase short-chain fatty acid concentrations in rodents. The broader resistant-starch literature supports a fermentation-dependent GLP-1/PYY pathway, but the complete pathway is not established for banana preparations in humans. Banana extracts show enzyme-inhibitory, anti-adipogenic and anti-inflammatory activities in preclinical models. These cannot generally be assigned to phenolics alone, and some individually tested constituents are non-polyphenolic. Several links in the gut–liver pathway and adipose-tissue macrophage reprogramming remain unverified with banana preparations. Some short-term human studies report lower postprandial glycaemia, whereas longer studies provide inconsistent evidence and limited between-group support.
Conclusions
Preclinical support is coherent and justifies further investigation of characterised banana preparations in order to conclude on clinical efficacy or permit the general attribution of their effects to individual compounds.
Zitieren
APA
Warnery, A., Silvestre, C., Antih, J., Portet, K., Vesta, G., Bruno-Bonnet, C., & Poucheret, P. (2026). Mechanisms of Action and Critical Appraisal of Preclinical and Clinical Evidence for Green Banana (Musa spp.) and Banana-Derived Preparations in Obesity, Metabolic Syndrome and Type 2 Diabetes: A Narrative Review. Foods, 15(22), 4067. https://doi.org/10.3390/foods15224067
Vancouver
Warnery A, Silvestre C, Antih J, Portet K, Vesta G, Bruno-Bonnet C, et al. Mechanisms of Action and Critical Appraisal of Preclinical and Clinical Evidence for Green Banana (Musa spp.) and Banana-Derived Preparations in Obesity, Metabolic Syndrome and Type 2 Diabetes: A Narrative Review. Foods. 2026;15(22):4067. doi:10.3390/foods15224067
BibTeX
@article{Warnery2026,
author = {Warnery, Audrey and Silvestre, Charlotte and Antih, Julien and Portet, Karine and Vesta, Gaëlle and Bruno-Bonnet, Christelle and Poucheret, Patrick},
title = {Mechanisms of Action and Critical Appraisal of Preclinical and Clinical Evidence for Green Banana (Musa spp.) and Banana-Derived Preparations in Obesity, Metabolic Syndrome and Type 2 Diabetes: A Narrative Review},
journal = {Foods},
year = {2026},
volume = {15},
number = {22},
pages = {4067},
doi = {10.3390/foods15224067}
}
EUVIMED